Literature DB >> 12148332

[How much does the medical treatment of chronic Chagas cardiopathy cost? Direct costs in a cardiology hospital].

Maite Vallejo1, Pablo Montenegro, Pedro A Reyes.   

Abstract

OBJECTIVE: To estimate health care costs of patients with chronic Chagasic cardiomyopathy (CCC) in a cardiovascular referral center (Instituto Nacional de Cardiología I. Chávez).
MATERIAL AND METHODS: In a retrospective study, 13 clinical charts of CCC patients treated in the hospital during 1998 were reviewed. Diagnostic and therapeutic procedures and patients admission were identify as well as health care costs, which were drawn from the hospital costs system.
RESULTS: 62% of the cases were admitted to the hospital through the out-patient facilities. All the patients had a health care subsidy of 15 to 55% allocated to the institutional budget. Health care costs were calculated for minimal, average, and maximum scenarios, according to the patient's clinical stage and the price of medical equipment used (low, medium, and high). Most of the health care costs are due to the use of high cost diagnostic equipment (33 a 58%) and hospital stay (including the emergency room) (19 a 28%).
CONCLUSION: This is the first approximation to the economic study of Chagas disease in Mexico, providing foundations for further studies on health economics and quality care of CCC, and suggests that prevention should be enhanced.

Entities:  

Mesh:

Year:  2002        PMID: 12148332

Source DB:  PubMed          Journal:  Arch Cardiol Mex        ISSN: 1665-1731


  8 in total

1.  Modeling the economic value of a Chagas' disease therapeutic vaccine.

Authors:  Bruce Y Lee; Kristina M Bacon; Angela R Wateska; Maria Elena Bottazzi; Eric Dumonteil; Peter J Hotez
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

Review 2.  Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects.

Authors:  Eric Dumonteil; Maria Elena Bottazzi; Peter J Hotez; Bin Zhan; Michael J Heffernan; Kathryn Jones; Jesus G Valenzuela; Shaden Kamhawi; Jaime Ortega; Samuel Ponce de Leon Rosales; Bruce Y Lee; Kristina M Bacon; Bernhard Fleischer; B T Slingsby; Miguel Betancourt Cravioto; Roberto Tapia-Conyer
Journal:  Expert Rev Vaccines       Date:  2012-09       Impact factor: 5.217

3.  Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease.

Authors:  Edeltraud J Lenk; William K Redekop; Marianne Luyendijk; Christopher Fitzpatrick; Louis Niessen; Wilma A Stolk; Fabrizio Tediosi; Adriana J Rijnsburger; Roel Bakker; Jan A C Hontelez; Jan H Richardus; Julie Jacobson; Epke A Le Rutte; Sake J de Vlas; Johan L Severens
Journal:  PLoS Negl Trop Dis       Date:  2018-03-13

4.  Comparison of 1-year healthcare resource utilization and related costs for patients with heart failure in the Chagas and non-Chagas matched cohorts.

Authors:  Mario J Olivera; Adriana Arévalo; Lyda Muñoz; Sofía Duque; Juan Bedoya; Gabriel Parra-Henao
Journal:  Ther Adv Infect Dis       Date:  2022-07-23

Review 5.  Risk of COVID-19 in Chagas Disease Patients: What Happen with Cardiac Affectations?

Authors:  Alejandro Diaz-Hernandez; Maria Cristina Gonzalez-Vazquez; Minerva Arce-Fonseca; Olivia Rodriguez-Morales; Maria Lilia Cedilllo-Ramirez; Alejandro Carabarin-Lima
Journal:  Biology (Basel)       Date:  2021-05-06

6.  The costs of preventing and treating chagas disease in Colombia.

Authors:  Marianela Castillo-Riquelme; Felipe Guhl; Brenda Turriago; Nestor Pinto; Fernando Rosas; Mónica Flórez Martínez; Julia Fox-Rushby; Clive Davies; Diarmid Campbell-Lendrum
Journal:  PLoS Negl Trop Dis       Date:  2008-11-18

7.  Opportunity cost for early treatment of Chagas disease in Mexico.

Authors:  Janine M Ramsey; Miguel Elizondo-Cano; Gilberto Sanchez-González; Adriana Peña-Nieves; Alejandro Figueroa-Lara
Journal:  PLoS Negl Trop Dis       Date:  2014-04-17

Review 8.  Chagas disease in the 21st century: a public health success or an emerging threat?

Authors:  Kevin M Bonney
Journal:  Parasite       Date:  2014-03-10       Impact factor: 3.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.